The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.
Source: MedTech Dive
You may also like
Copay Assistance Is Meant To Defray Patient Drug...
Patients Face a Thicket of Red Tape Trying To Maintain...
Affordable Care Act Insurers Want More Premium...
As GOP Cries Fraud, Newsom Backs Medicaid Spending on...
Edwards will pay $10M to settle FTC charges of...
HHS watchdog says it’s targeting Medicaid, Medicare...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.